Announced Sun, 23 Aug, 2026 · 12:33 IST
Zydus Lifesciences Investor Presentation for Aug 2026 Conference
Mgmt Guided Margin ImprovementPromoter Disclosed Acquisition PlansOrder Pipeline DisclosedAnalyst Day Multiyear TargetsInvestor Communications View source PDFExplain this filing
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.4%1-day move
₹1120.00
prior close
₹1112.70
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4-0.5-0.6-0.4+0.4+2.6+6.0+5.8+3.7+3.1-1.9+5.4——
Up moveDown movePending
AI summary
Zydus Lifesciences filed its August 2026 investor presentation for investor meet Aug 24-26. FY26 revenue was USD 3 billion plus with EBITDA of USD 959 million at 31.2 percent margin. Q1FY27 revenue grew 21.9 percent YoY to INR 80,170 million. Management highlighted Saroglitazar NDA receiving USFDA priority review with Q4FY27 approval expected, plus biosimilars, vaccines pipeline, and Comfort Click and Amplitude Surgical acquisitions. ROCE improved to 21.6 percent.
Likely market impact
Positive read with sustained revenue and margin growth, strong innovation pipeline, and continued acquisitions driving future expansion